{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Mexico Biotechnology news", "home_page_url": "https://sharemaestro.com/newsreel/mx/healthcare/biotechnology/", "feed_url": "https://sharemaestro.com/newsreel/mx/healthcare/biotechnology/feed.json", "description": "Latest Biotechnology company headlines from Mexico, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:8dc71079705610a28482643141072be9f4ca1d8b708f06563b733048af9fa884", "url": "https://finance.yahoo.com/healthcare/articles/biomarin-pharmaceutical-bmrn-outperforming-other-134002976.html", "external_url": "https://finance.yahoo.com/healthcare/articles/biomarin-pharmaceutical-bmrn-outperforming-other-134002976.html", "title": "Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year?", "content_text": "Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is BioMarin Pharmaceutical (BMRN) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. BioMarin Pharmaceutical is one of 914 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to ", "date_published": "2026-08-14T13:40:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BMRN"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BMRN", "name": "BioMarin Pharmaceutical Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/d0f5aa32-f8a9-4e82-af3c-242000942513/"}]}}, {"id": "source:eff5922e101371e66c6fa7e287bc65b5cf721f7fc28b7dab3b5aa6a295c6bcc3", "url": "https://finance.yahoo.com/markets/stocks/articles/zacks-com-featured-highlights-biomarin-093800634.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/zacks-com-featured-highlights-biomarin-093800634.html", "title": "Zacks.com featured highlights include BioMarin Pharmaceutical, Invesco, Centene Corporation, Hewlett Packard Enterprise and Gibraltar Industries", "content_text": "For Immediate Release Chicago, IL \u2013 August 14, 2026 \u2013 Stocks in this week's article are BioMarin Pharmaceutical BMRN, Invesco IVZ, Centene Corporation CNC, Hewlett Packard Enterprise HPE and Gibraltar Industries ROCK. 5 Undervalued Price-to-Book Stocks Worth Buying in August There are several different ways to find value stocks. Among these, the most popular are the price-to-earnings ratio (P/E) and the price-to-sales ratio (P/S). However, investors often overlook the price-to-book ratio (P/B ratio), which, though used less often, is also an easy-to-use valuation tool for identifying low-price", "date_published": "2026-08-14T09:38:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "BMRN"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BMRN", "name": "BioMarin Pharmaceutical Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/d0f5aa32-f8a9-4e82-af3c-242000942513/"}]}}, {"id": "source:fa653b52a5fbc565a19314567340cb7551b5057eca6e4c32041314cb69b78de4", "url": "https://finance.yahoo.com/healthcare/articles/could-arcus-biosciences-rcus-summit-000349349.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-arcus-biosciences-rcus-summit-000349349.html", "title": "Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)\u2019s Cancer Drug Partnership Create a New Treatment Standard?", "content_text": "On July 22, Arcus Biosciences, Inc. (NYSE:RCUS) and Summit Therapeutics Inc. (NASDAQ:SMMT) announced a major clinical trial collaboration to combine Arcus's casdatifan (an investigational HIF-2\u03b1 inhibitor) with Summit's ivonescimab (an investigational PD-1/VEGF bispecific antibody). The study aims to evaluate the safety and efficacy of this combination in clear cell renal cell carcinoma (ccRCC), including first-line metastatic disease. Arcus CEO Terry Rosen highlighted the opportunity to establish a well-tolerated, TKI-sparing regimen that could prolong survival and serve as a first-line backb", "date_published": "2026-08-14T00:03:49+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "SMMT"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SMMT", "name": "Summit Therapeutics Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/2c1758ce-a02e-47ef-b431-b60536a5b452/"}]}}, {"id": "source:d24f03e171dcc6919f537e9491918e8c8f9a33221c26e24cf2891fd1bebba413", "url": "https://finance.yahoo.com/healthcare/articles/could-hca-healthcare-inc-hca-221733771.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-hca-healthcare-inc-hca-221733771.html", "title": "Could HCA Healthcare, Inc. (HCA) Stock Rebound After Guidance Cuts and Payer Pressure?", "content_text": "HCA Healthcare, Inc. (NYSE:HCA) reported its second-quarter 2026 financial results on July 24, confirming the figures previewed earlier in the month. While top-line growth remained healthy, a visible deterioration in payer mix and a revision to full-year profitability guidance triggered immediate target cuts across Wall Street. In its Q2 results, HCA Healthcare, Inc. reported that revenue increased 8.7% year-over-year to $20.23 billion from $18.61 billion in Q2 2025. The firm's net income attributable to the company rose 2.8% to $1.69 billion, while diluted EPS increased 11.6% to $7.62 (or $7.", "date_published": "2026-08-13T22:17:33+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "SMMT"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "SMMT", "name": "Summit Therapeutics Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/2c1758ce-a02e-47ef-b431-b60536a5b452/"}]}}, {"id": "source:3e581f92470f4b5afab1cad30e71ada24f26051a1dff74f9e42be0e418df6277", "url": "https://www.nasdaq.com/articles/ocugen-ocgn-q2-2026-earnings-call-transcript", "external_url": "https://www.nasdaq.com/articles/ocugen-ocgn-q2-2026-earnings-call-transcript", "title": "Ocugen (OCGN) Q2 2026 Earnings Call Transcript", "content_text": "Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chairman, Chief Executive Officer, and Co-Founder - Shankar MusunuriChief Financial Officer - Rita Johnson-GreeneExecutive Vice President of Commercial and Business Development - Abhi GuptaChief Medical Officer - Mohamed GeneadHead of Communications - Chris Clark Need a quote from a Motley Fool analyst? Email pr@fool.com TAKEAWAYS Cash, Cash Equivalents, and Restricted Cash -- $100.4 million as of June 30, 2026, compared to $32.2 million as of March 31, 2026.Cash Runway -- Extended into 2028 following ", "date_published": "2026-08-13T18:14:44+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "OCGN"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "OCGN", "name": "Ocugen, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/9feac636-96f2-4cb4-9ae2-979e66131a4b/"}]}}, {"id": "source:3a388e494f79e0e3d0cddb545f7d140c86ccb65e69ffa3d6ea2be4a007931c6b", "url": "https://www.nasdaq.com/articles/inovio-ino-q2-2026-earnings-call-transcript", "external_url": "https://www.nasdaq.com/articles/inovio-ino-q2-2026-earnings-call-transcript", "title": "Inovio (INO) Q2 2026 Earnings Call Transcript", "content_text": "Image source: The Motley Fool. DATE Wednesday, Aug. 12, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Director of Communications - Jennie WillsonPresident and Chief Executive Officer - Dr. Jacqueline E. SheaChief Medical Officer - Dr. Michael SumnerChief Commercial Officer - Steven EggeChief Financial Officer - Peter D. Kies TAKEAWAYS INO-3107 PDUFA Date -- Oct. 30, 2026, for the Inovio Pharmaceuticals, Inc.(NASDAQ:INO) Biologics License Application (BLA), representing the target action date for regulatory review.Cash and Cash Equivalents -- $36.7 million as of June 30, 2026, a decrease from $58.5 mi", "date_published": "2026-08-13T00:58:58+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "INO"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "INO", "name": "Inovio Pharmaceuticals, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/f766a58a-bff4-4514-82e8-d167c9f3b129/"}]}}, {"id": "source:47aa952b2ea16a49ab384746472151b2084c4610ac379e9e548a30ef91b2c17f", "url": "https://seekingalpha.com/news/4631600-fibrogen-q2-2026-earnings-preview?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4631600-fibrogen-q2-2026-earnings-preview?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "FibroGen Q2 2026 Earnings Preview", "content_text": "* FibroGen (KYNB [https://seekingalpha.com/symbol/KYNB]) is scheduled to announce Q2 earnings results on Thursday, August 13th, after market close. * The consensus EPS estimate is -$3.18, [https://seekingalpha.com/symbol/KYNB/earnings/estimates] and the consensus revenue estimate is $2.01M (+48.9% Y/Y). * Over the last 3 months, EPS estimates have seen 1 upward revision [https://seekingalpha.com/symbol/KYNB/earnings/revisions] and 1 downward. Revenue estimates have seen 1 upward revision and 1 downward. MORE ON FIBROGEN * Seeking Alpha\u2019s Quant Rating on FibroGen [https://seekingalpha.com/symbo", "date_published": "2026-08-12T21:35:54+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Earnings", "KYNB"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "KYNB", "name": "Kyntra Bio, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/acf4e837-cb0e-4313-bee2-27be0e439350/"}]}}, {"id": "source:d0ac47e16e7fd03e7bec5599cff2efbd3adaf08173d18bbc5a02125b07eddbbf", "url": "https://finance.yahoo.com/markets/stocks/articles/stocks-wall-street-betting-against-193023310.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/stocks-wall-street-betting-against-193023310.html", "title": "These Are the Stocks Wall Street Is Betting Against the Most", "content_text": "This article first appeared on GuruFocus. The supplied source only contains the heatmap headline and ticker list, without the underlying short-interest percentages or ranking data. I can write the story accurately from that limited information, but I would not invent figures. A group of heavily shorted stocks is drawing renewed attention as investors track companies facing elevated bearish positioning, with Wolfspeed (NYSE:WOLF), Purple Innovation (NASDAQ:PRPL), Recursion Pharmaceuticals (NASDAQ:RXRX) and Intellia Therapeutics (NTLA) among the names highlighted in a recent short-interest heatm", "date_published": "2026-08-12T19:30:23+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "RXRX"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "RXRX", "name": "RECURSION PHARMACEUTICALS INC", "sentiment_url": "https://sharemaestro.com/sentiment/7bb72e3e-f732-4308-b18d-13845b1a4811/"}]}}, {"id": "source:00c54625669f68699f20b1d95e9b719c7abfecb0c33a173abd9e9ac759ec65b6", "url": "https://seekingalpha.com/news/4631777-altimmune-outlines-performa-phase-iii-mash-52-week-data-readout-expected-in-2029-while?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4631777-altimmune-outlines-performa-phase-iii-mash-52-week-data-readout-expected-in-2029-while?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Altimmune outlines PERFORMA Phase III MASH 52-week data readout expected in 2029 while advancing AUD Phase III planning", "content_text": "Earnings Call Insights: Altimmune (ALT) Q2 2026 MANAGEMENT VIEW * \"2026 is proving to be a year of significant progress as Altimmune evolves into a late-stage company dedicated to serious liver diseases,\" said Chairman, CEO & President Jerome Durso, adding, \"Last week we announced the initiation of the PERFORMA Phase III trial as we began enrolling patients in the global program\" (Chairman, CEO & President Jerome Durso). * \"We were pleased to report positive top-line data from the RECLAIM Phase II trial\" and \"Pemvidutide delivered a very strong, statistically significant, and clinically meanin", "date_published": "2026-08-12T18:38:11+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Earnings", "ALT1"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ALT1", "name": "Altimmune, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/a48f382e-c110-468c-9c9b-b2fb91dd0dd3/"}]}}, {"id": "source:55c67ba2272dea5cc0cd1ede8ac29dbc25eda74abf99d734107491a87e3cb10b", "url": "https://finance.yahoo.com/markets/stocks/articles/bmrn-vs-ilmn-stock-better-154005188.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/bmrn-vs-ilmn-stock-better-154005188.html", "title": "BMRN vs. ILMN: Which Stock Is the Better Value Option?", "content_text": "Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either BioMarin Pharmaceutical (BMRN) or Illumina (ILMN). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits", "date_published": "2026-08-12T15:40:05+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BMRN"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BMRN", "name": "BioMarin Pharmaceutical Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/d0f5aa32-f8a9-4e82-af3c-242000942513/"}]}}, {"id": "source:382c5f901b3fe24d52e18b823bbce0bd9ccc848d9b2a6c3a8e46d6d6e92c6cd4", "url": "https://finance.yahoo.com/healthcare/articles/biomarin-pharmaceutical-bmrn-stock-know-152522069.html", "external_url": "https://finance.yahoo.com/healthcare/articles/biomarin-pharmaceutical-bmrn-stock-know-152522069.html", "title": "BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know", "content_text": "BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know What Happened? Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 2.6% in the morning session after an analyst at Canaccord Genuity raised the company's price target to $114 from $111 and maintained a \"Buy\" rating. The positive revision followed BioMarin's strong second-quarter 2026 earnings report. The company's revenue growth was driven by the addition of products from the recently closed Amicus acquisition. Following the strong results, BioMarin raised its fiscal 2026 guidance for total revenue, Voxzogo re", "date_published": "2026-08-12T15:25:22+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BMRN"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BMRN", "name": "BioMarin Pharmaceutical Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/d0f5aa32-f8a9-4e82-af3c-242000942513/"}]}}, {"id": "source:15cb90517d578b763e104c2e95c03c45b13caec26d6615a176e3914e9290a3ac", "url": "https://finance.yahoo.com/healthcare/articles/vertex-multiple-portfolio-catalysts-favorable-150252779.html", "external_url": "https://finance.yahoo.com/healthcare/articles/vertex-multiple-portfolio-catalysts-favorable-150252779.html", "title": "Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says", "content_text": "Vertex Pharmaceuticals (VRTX) has multiple potential catalysts coming from its portfolio that provide a net positive risk-reward profile for the company, RBC Capital Markets said in a Wednesday note.The company is expected to present results from its phase 1 study of VX-828 in Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "date_published": "2026-08-12T15:02:52+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "VRTX"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VRTX", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/fe76b9a5-9d69-445d-a49e-e107f61ffc89/"}]}}, {"id": "source:01d5df0eb54c38965e649f5ffd410ea7b04c6d9669440b16e42840f13bafe9ea", "url": "https://seekingalpha.com/news/4631512-summit-lead-drug-granted-china-label-expansion?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4631512-summit-lead-drug-granted-china-label-expansion?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Summit higher as partner Akeso wins China label expansion for lead drug", "content_text": "[Approved red stamp sign.] * Shares of Summit Therapeutics (SMMT [https://seekingalpha.com/symbol/SMMT]) traded higher on Wednesday after the Chinese drug regulator, the National Medical Products Administration, approved a label expansion for the company\u2019s lead drug, ivonescimab, developed with Akeso (AKESF [https://seekingalpha.com/symbol/AKESF]). * According to Summit (SMMT [https://seekingalpha.com/symbol/SMMT]), the NMPA granted marketing authorization for the first-line use of ivonescimab in combination with chemotherapy for advanced squamous non-small cell lung cancer, marking the third ", "date_published": "2026-08-12T14:21:57+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Regulatory and legal", "SMMT"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SMMT", "name": "Summit Therapeutics Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/2c1758ce-a02e-47ef-b431-b60536a5b452/"}]}}, {"id": "source:effa4ed1caf33496b3380870fdaa9fab5b585d707cfd898d9224cf86f7ba93bf", "url": "https://finance.yahoo.com/healthcare/articles/biomarin-targets-faster-deleveraging-amicus-140505463.html", "external_url": "https://finance.yahoo.com/healthcare/articles/biomarin-targets-faster-deleveraging-amicus-140505463.html", "title": "BioMarin Targets Faster Deleveraging as Amicus Deal Expands Rare-Disease Growth", "content_text": "Key Points Interested in BioMarin Pharmaceutical Inc.? Here are five stocks we like better. BioMarin raised its financial outlook after second-quarter revenue approached $1 billion, lifting 2025 revenue guidance to $3.875 billion\u2013$3.925 billion and non-GAAP EPS guidance to $4.90\u2013$5.10. The Amicus acquisition added Galafold and the Pombiliti/Opfolda Pompe franchise, with significant geographic expansion and diagnosis opportunities. BioMarin now expects to reduce leverage below 2.5 times by mid-next year, about a year ahead of its original target, while preserving Amicus' commercial capabilities", "date_published": "2026-08-12T14:05:05+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BMRN"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BMRN", "name": "BioMarin Pharmaceutical Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/d0f5aa32-f8a9-4e82-af3c-242000942513/"}]}}, {"id": "source:2b89a6c256b10059dd50a2c3552aea4cb75cb48d535895085ee95232921aad1e", "url": "https://finance.yahoo.com/healthcare/articles/ivonescimab-combination-chemotherapy-approved-china-132200149.html", "external_url": "https://finance.yahoo.com/healthcare/articles/ivonescimab-combination-chemotherapy-approved-china-132200149.html", "title": "Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer", "content_text": "Marks Third NMPA Approval in China for an Ivonescimab-Containing Regimen NMPA Approval Based on HARMONi-6 Clinical Trial Conducted by Akeso in China Ivonescimab in Combination with Chemotherapy Is the First Known Regimen to Achieve a Statistically Significant Overall Survival Benefit over an Anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in NSCLC or Any Tumor Type MIAMI, August 12, 2026--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that, on August 12, 2026, its partner Akeso Inc. (Akeso, HKEX Code: 9926.HK) announced receipt of marketing ", "date_published": "2026-08-12T13:22:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "SMMT"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "SMMT", "name": "Summit Therapeutics Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/2c1758ce-a02e-47ef-b431-b60536a5b452/"}]}}, {"id": "source:46b3f23a3cbbf72aa4fa4eff600d629dac6ffd5d600b532526e1abeb25fd4333", "url": "https://seekingalpha.com/news/4631498-uk-regulator-reaffirms-safety-of-childhood-vaccination?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4631498-uk-regulator-reaffirms-safety-of-childhood-vaccination?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "U.K. regulator reaffirms safety of childhood vaccination", "content_text": "[Syringe drawing liquid medication from medical vial] zhikun sun/iStock via Getty Images Days after President Donald Trump ordered major changes to the U.S. childhood immunization schedule, the U.K. drug regulator on Wednesday reaffirmed the safety of pediatric vaccination, noting it remains one of the safest and most effective ways to fight many severe infectious diseases. Issuing an executive order to reduce the number of childhood vaccines administered in the U.S. and split the measles, mumps, and rubella vaccination into three separate shots on Monday, Trump suggested a link between vaccin", "date_published": "2026-08-12T13:13:40+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Market update", "NVAX"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NVAX", "name": "Novavax, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/5636c4cf-7d84-42fb-bf59-c27bb981cb76/"}]}}, {"id": "source:77c9df0ffab0dcaff3034f70e888688fbcf314006ca5b7527e8fc365cf5026bf", "url": "https://finance.yahoo.com/healthcare/articles/one-company-clinical-miss-another-034131355.html", "external_url": "https://finance.yahoo.com/healthcare/articles/one-company-clinical-miss-another-034131355.html", "title": "One Company\u2019s Clinical Miss Is Another\u2019s Moat: Vertex Rallies as Sionna\u2019s CF Bet Collapses", "content_text": "Cystic fibrosis investors came to learn a harsh lesson on August 10 about how concentrated a market can be: Sionna Therapeutics, Inc. (NASDAQ:SION) shares fell more than 90% following a key trial failure, while Vertex Pharmaceuticals (NASDAQ:VRTX), the company whose drug dominance Sionna was attempting to challenge, surged to new highs. The Pipeline Flop Sionna Therapeutics, Inc. (NASDAQ:SION) announced the topline results of its Phase 2a \"PreciSION CF\" trial the morning of August 10, which tested its lead drug candidate SION-719 as a complementary therapy to Vertex's blockbuster Trikafta regimen. Beyond its primary safety goal, the trial's objective was to demonstrate that SION-719 could significantly increase CFTR protein function, measured via sweat chloride levels, over Trikafta alone. It didn't. The trial failed to meet its main activity endpoint, and Sionna Therapeutics, Inc. (NASDAQ:SION) has decided not to proceed SION-719 as a Trikafta add-on. The company noted some complicating aspects of the data, such as greater variability than anticipated in individual sweat chloride readings and inconsistent Trikafta exposure between treatment and placebo groups. That said, the bottom line for investors was clear: a well-funded challenger's leading clinical asset in CF had failed. Sionna Therapeutics, Inc. (NASDAQ:SION) wasn't completely wiped out on the day. A different, earlier-stage Phase 1 trial of its SION-451 combo program met its safety and pharmacokinetic targets, and the company says it will now prioritize that program instead. However, with over $268 million in cash and a lead program shelved, Sionna's stock reaction shows how much of its valuation was dependent on SION-719 succeeding. De-Risked Moat and Unrivaled Dominance For years, Vertex Pharmaceuticals (NASDAQ:VRTX) has enjoyed a near-monopoly in cystic fibrosis treatment, thanks to Trikafta and its successor Alyftrek. Given the extent of this dominance, any credible challenger's data has become a legitimate risk factor for the stock, with traders having openly cited Sionna's pipeline as an overhang on Vertex Pharmaceuticals (NASDAQ:VRTX), especially since a working NBD1 stabilizer could have harmed Trikafta's business. With the immediate threat removed, the market re-rated Vertex higher. That said, it's important to note that Vertex Pharmaceuticals (NASDAQ:VRTX) did not start from scratch. Shares were already up year-to-date, trading around record levels following a solid second quarter that included higher full-year revenue guidance and a proposed $10 billion acquisition of Crinetics Pharmaceuticals to expand into endocrinology. Story Continues Smart Money Sentiment Prior to the readout, smart money positions on Wall Street indicated two separate risk profiles. Insider Monkey's Q1 2026 data shows that hedge fund positions in Sionna Therapeutics, Inc. (NASDAQ:SION) increased from 23 in Q4 to 32 in Q1, as speculative investors positioned for a potential catalyst beat. However, this accumulation coincided with a significant 19.73% short interest rate, suggesting heavy institutional skepticism. Meanwhile, Vertex Pharmaceuticals (NASDAQ:VRTX) had strong institutional support with low short interest. Hedge fund ownership increased from 64 in the fourth quarter of the preceding year to 68 in the first quarter of 2026, while short interest was low at 1.97% of the float. Insider Monkey's Verdict The results are a reminder of Vertex Pharmaceuticals (NASDAQ:VRTX)'s status as the undisputed leader in cystic fibrosis. The healthcare giant remains a favorite institutional holding due to growing cash flows and a strategic push into endocrinology. Meanwhile, Sionna Therapeutics, Inc. (NASDAQ:SION) is morphing into a high-risk micro-cap restructurer where capital preservation and early-stage SION-451 data will determine any multi-year turnaround. While we acknowledge the potential of VRTX as an investment, we believe certain AI stocks offer greater upside potential and carry les", "date_published": "2026-08-12T03:41:31+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "VRTX"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "VRTX", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/fe76b9a5-9d69-445d-a49e-e107f61ffc89/"}]}}, {"id": "source:55a3270eab70bcb7bf8317e3b4c68cd08419056da1e9e96c4e285557febdbf61", "url": "https://finance.yahoo.com/healthcare/articles/5-insightful-analyst-questions-vertex-014122962.html", "external_url": "https://finance.yahoo.com/healthcare/articles/5-insightful-analyst-questions-vertex-014122962.html", "title": "5 Insightful Analyst Questions From Vertex Pharmaceuticals\u2019s Q2 Earnings Call", "content_text": "5 Insightful Analyst Questions From Vertex Pharmaceuticals's Q2 Earnings Call Vertex Pharmaceuticals' second quarter reflected strong commercial momentum, with management highlighting the performance of its cystic fibrosis (CF) portfolio and accelerating uptake of newer products like CASGEVY and JOURNAVX. CEO Reshma Kewalramani attributed revenue growth to \"the strength of our cystic fibrosis portfolio and the growing contributions from our newer products,\" while also emphasizing progress in regulatory and clinical milestones. Management specifically noted that ALYFTREK and TRIKAFTA continued to drive CF revenue, and that European launches benefitted from fewer monitoring requirements. Is now the time to buy VRTX? Find out in our full research report (it's free). Vertex Pharmaceuticals (VRTX) Q2 CY2026 Highlights: Revenue: $3.33 billion vs analyst estimates of $3.19 billion (12.5% year-on-year growth, 4.6% beat) Adjusted EPS: $4.73 vs analyst expectations of $4.75 (in line) Adjusted Operating Income: $1.42 billion vs analyst estimates of $1.37 billion (42.7% margin, 3.9% beat) The company slightly lifted its revenue guidance for the full year to $13.15 billion at the midpoint from $13.03 billion Operating Margin: 37.4%, down from 38.8% in the same quarter last year Market Capitalization: $125.7 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Our Top 5 Analyst Questions From Vertex Pharmaceuticals's Q2 Earnings Call Salveen Richter (Goldman Sachs): Asked about the Phase II/III OLYMPUS study dose selection for Pove in membranous nephropathy and bottlenecks in JOURNAVX's payer dynamics. CEO Reshma Kewalramani clarified the Data Safety Monitoring Board's role in dose selection and Duncan McKechnie highlighted ongoing efforts to secure broader access for JOURNAVX. Geoffrey Meacham (Citibank): Inquired about desired clinical outcomes for next-generation CF therapies and payer feedback on JOURNAVX in diabetic peripheral neuropathy. Kewalramani said efficacy and safety are the main goals, with further data and payer perspectives expected in coming quarters. Jessica Fye (JPMorgan): Asked about expected differentiation on eGFR endpoints for new IgAN treatments. Kewalramani explained that long-term benefits will depend on time to end-stage renal disease and the ability to achieve deeper reductions in proteinuria and hematuria. Cory Kasimov (Evercore ISI): Sought clarity on interim analysis criteria for inaxaplin in AMPLITUDE and accelerated approval. Kewalramani said the FDA agreement focuses on 1-year GFR as the primary endpoint for the interim analysis. Mohit Bansal (Wells Fargo): Queried prescription duration trends for JOURNAVX. McKechnie noted average durations have remained stable at around 10\u201311 days per prescription, split between hospital and retail settings. Story Continues Catalysts in Upcoming Quarters In coming quarters, the StockStory team will be watching (1) the pace of ALYFTREK adoption and label expansions in CF, (2) launch execution and patient uptake for CASGEVY and JOURNAVX, and (3) regulatory progress and launch timing for Pove in IgAN and the integration of Crinetics' assets. Progress in clinical data readouts for next-generation CF and renal assets will also be key signposts. Vertex Pharmaceuticals currently trades at $496.00, up from $470.72 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it's free for active Edge members). High-Quality Stocks for All Market Conditions ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectivel", "date_published": "2026-08-12T01:41:22+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "VRTX"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VRTX", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/fe76b9a5-9d69-445d-a49e-e107f61ffc89/"}]}}, {"id": "source:3cfb868535c8a5784eb5addfcc92c8b6baad04926dc931f4109d4134ca291373", "url": "https://seekingalpha.com/news/4630680-here-are-the-major-earnings-before-the-open-wednesday?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4630680-here-are-the-major-earnings-before-the-open-wednesday?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Here are the major earnings before the open Wednesday", "content_text": "Major earnings expected before the bell on Wednesday include: * Nebius Group N.V. (NBIS [https://seekingalpha.com/symbol/NBIS]) * Tencent Holdings Limited (TCEHY [https://seekingalpha.com/symbol/TCEHY]) * Brinker International (EAT [https://seekingalpha.com/symbol/EAT]) * Amcor plc (AMCR [https://seekingalpha.com/symbol/AMCR]) * Jumia Technologies AG (JMIA [https://seekingalpha.com/symbol/JMIA]) Other earnings slated for release before Wednesday's open include: * ACDVF [https://seekingalpha.com/symbol/ACDVF], ALLT [https://seekingalpha.com/symbol/ALLT], ALT [https://seekingalpha.com/symbol/ALT", "date_published": "2026-08-11T22:00:22+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Earnings", "ALT1"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ALT1", "name": "Altimmune, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/a48f382e-c110-468c-9c9b-b2fb91dd0dd3/"}]}}, {"id": "source:53cc432f14abb35ffed3db91463a6293235493ffceb9c8726e1f81b504292231", "url": "https://finance.yahoo.com/healthcare/articles/kod-begins-stage-study-ksi-151500677.html", "external_url": "https://finance.yahoo.com/healthcare/articles/kod-begins-stage-study-ksi-151500677.html", "title": "KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema", "content_text": "Kodiak Sciences KOD announced that it initiated a global late-stage ALTO study evaluating KSI-501 in patients with diabetic macular edema (DME). KSI-501 is an investigational bispecific therapy that targets IL-6 and VEGF for the treatment of retinal vascular diseases. Patient enrollment is ongoing. DME is a complex, multi-factorial condition in which vascular leakage, disruption of the blood-retinal barrier, and chronic inflammatory signaling collectively contribute to retinal edema and vision loss. Year to date, Kodiak's shares have risen 55.2% compared with the industry's 6% growth.Zacks Inv", "date_published": "2026-08-11T15:15:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "ALT1"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ALT1", "name": "Altimmune, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/a48f382e-c110-468c-9c9b-b2fb91dd0dd3/"}]}}, {"id": "source:307c68c8377bcf013ad783581ce907b734df56f45e0558685346ed0bf0510ade", "url": "https://finance.yahoo.com/healthcare/articles/regn-soars-21-9-month-143000494.html", "external_url": "https://finance.yahoo.com/healthcare/articles/regn-soars-21-9-month-143000494.html", "title": "REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?", "content_text": "The going has been strong for Regeneron Pharmaceuticals REGN over the past month. Shares of this biotech giant have surged 21.9% over the said time frame, outpacing the industry's growth of 4%. The stock has also outperformed the sector and the S&P 500 Index during this time. REGN's robust rally has been driven by better-than-expected quarterly results, which can be attributed to robust demand for Eylea HD (higher dose of Eylea) and higher profit-sharing from Dupixent that helped the company mitigate the decline in Eylea sales. REGN Outperforms Industry, Sector and S&P 500 IndexZacks Investmen", "date_published": "2026-08-11T14:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "REGN"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "REGN", "name": "Regeneron Pharmaceuticals, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/fef373b5-80a0-4165-b299-994d5adb942b/"}]}}, {"id": "source:087d578d3f75d830d50d54bbb4f31de98eb6f9576d94fb132b7fae0ab08fa04b", "url": "https://finance.yahoo.com/healthcare/articles/non-viral-transfection-reagents-market-084500474.html", "external_url": "https://finance.yahoo.com/healthcare/articles/non-viral-transfection-reagents-market-084500474.html", "title": "Non-Viral Transfection Reagents Market Report (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User & Region, Featuring Bio-Rad, MaxCyte, MilliporeSigma, Thermo Fisher Scientific", "content_text": "Company Logo Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The \"Non-Viral Transfection Reagents Market (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User and Geographical Regions-Trends and Forecast Till 2035\" has been added to ResearchAndMarkets.com's offering. The global non-viral transfection reagents market is projected to increase from USD 0.89 billion in 2026 to USD 2.01 billion by 2035, expanding at a compound annual growth rate of 9.5% during the forecast period. Market growth is being driven by rising demand for nucleic acid-based therapeutics, continued in", "date_published": "2026-08-11T08:45:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Guidance", "DNA"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "DNA", "name": "Ginkgo Bioworks Holdings, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/bd0e4ac0-5171-421a-b6e7-d59461e303fe/"}]}}, {"id": "source:fafc61c50e634d6c45aecdb1952334394a1495194e5acc1d0607da1b1f8882e8", "url": "https://finance.yahoo.com/healthcare/articles/could-arbutus-biopharma-corporation-abus-001821145.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-arbutus-biopharma-corporation-abus-001821145.html", "title": "Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?", "content_text": "A landmark legal settlement in the biotech sector recently reshaped the financial trajectories of two key mRNA technology players: Arbutus Biopharma Corporation (NASDAQ:ABUS) and Moderna, Inc. (NASDAQ:MRNA). The resolution of their global patent infringement litigation over lipid nanoparticle (LNP) delivery technology provided Arbutus with a massive, non-dilutive liquidity boost while removing a significant overhang for Moderna as it seeks to expand its commercial pipeline beyond COVID-19.Could Arbutus Biopharma Corporation (ABUS) Turn Its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech", "date_published": "2026-08-11T00:18:21+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MRNA"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MRNA", "name": "Moderna, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/44b7313f-bff2-44ce-bdd7-cb74735027b8/"}]}}, {"id": "source:678ac623cf251081a7655bfded1093365a20b3f36408109d6dac91004725ab75", "url": "https://finance.yahoo.com/markets/stocks/articles/prokidney-corp-prok-reports-q2-215507627.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/prokidney-corp-prok-reports-q2-215507627.html", "title": "ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates", "content_text": "ProKidney Corp. (PROK) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.13 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -15.39%. A quarter ago, it was expected that this company would post a loss of $0.13 per share when it actually produced a loss of $0.14, delivering a surprise of -7.69%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. PROKIDNEY CP, which belongs to the Zacks Medic", "date_published": "2026-08-10T21:55:07+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PROK"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PROK", "name": "ProKidney Corp.", "sentiment_url": "https://sharemaestro.com/sentiment/730a76ac-cafa-4651-88e5-dfd38c144c11/"}]}}, {"id": "source:ded0a70177b84db5d31edd795e7c9d2e63b79dd04bf4873bd45caf2b7a3ddea1", "url": "https://finance.yahoo.com/healthcare/articles/prokidney-reports-second-quarter-2026-200500887.html", "external_url": "https://finance.yahoo.com/healthcare/articles/prokidney-reports-second-quarter-2026-200500887.html", "title": "ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights", "content_text": "ProKidney Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for anticipated pivotal eGFR slope topline results in Q2 2027 On track for completion of full enrollment for PROACT 1 in the second half of 2026 Appointed Kenneth Locke as Chief Technical Officer, adding more than 25 years of R&D, CMC and supply chain leadership experience Ended Q2 2026 with $181.6 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027 WINSTON-SALEM, N.C., Aug. 10, 2026 (GLOBE NEWSWIRE) -- P", "date_published": "2026-08-10T20:05:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PROK"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PROK", "name": "ProKidney Corp.", "sentiment_url": "https://sharemaestro.com/sentiment/730a76ac-cafa-4651-88e5-dfd38c144c11/"}]}}, {"id": "source:d76c6573caaf33a4540310495d2a64dece8f7b7d3633b25c5b87a2529c2af6b0", "url": "https://finance.yahoo.com/m/b81755ac-36bf-3983-868f-dada13133338/why-sionna-therapeutics-stock.html", "external_url": "https://finance.yahoo.com/m/b81755ac-36bf-3983-868f-dada13133338/why-sionna-therapeutics-stock.html", "title": "Why Sionna Therapeutics Stock Is Crashing 92% to a Record Low", "content_text": "The biotech says its cystic fibrosis drug candidate missed the mark in a Phase 2a trial, though the news could be a boon to shares of Vertex Pharmaceuticals. Continue Reading", "date_published": "2026-08-10T16:01:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "VRTX"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "VRTX", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/fe76b9a5-9d69-445d-a49e-e107f61ffc89/"}]}}, {"id": "source:205b512e8b0ffa6bb8920650c9ec23803fc8fef84bfcc769bbff60e8e4060989", "url": "https://finance.yahoo.com/markets/stocks/articles/vertex-stock-jumps-5-9-155537840.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/vertex-stock-jumps-5-9-155537840.html", "title": "Vertex Stock Jumps 5.9% as Rival Cystic Fibrosis Drug Fails", "content_text": "This article first appeared on GuruFocus. Vertex Pharmaceuticals (NASDAQ:VRTX), the biotech king of cystic fibrosis, jumped approximately 5.9% in Monday's regular session after a rival drug stumbled. Sionna Therapeutics said SION-719 missed the key activity endpoint in a Phase 2a trial when added to the current standard of care. Sionna is now dropping that specific add-on strategy. That is a clean win for Vertex without Vertex doing anything. One potential challenger just lost momentum, giving its enormously profitable cystic-fibrosis franchise more breathing room. Warning! GuruFocus has detected 4 Warning Signs with VRTX. Is VRTX fairly valued? Test your thesis with our free DCF calculator. The Sionna's clinical update showed only a limited reduction in sweat chloride, an important measure of cystic-fibrosis transmembrane conductance regulator function. Sionna is investigating what went wrong and still has other drug combinations in development, so the competitive threat has not disappeared. But investors do not need every rival to disappear. They need Vertex's moat to stay wide. And right now, it is doing exactly that. Second-quarter revenue climbed 12% to roughly $3.33 billion, while management raised full-year revenue guidance to $13.1 billion$13.2 billion. The longer Vertex protects that cash machine, the more time it gets to build its next act across pain, kidney disease and gene editing.Vertex Stock Jumps 5.9% as Rival Cystic Fibrosis Drug Fails\u00b7us.finance.gurufocus Here is where the story gets even more interesting. GuruFocus puts Vertex's GF Value at $519.20, versus Monday's $526.15 share price. That means the stock trades only 1.34% above GF Value even after the 5.9% surge. In other words, Wall Street just handed Vertex a competitive gift, the stock popped, and the valuation still sits remarkably close to estimated fair value. Sionna's failure will not magically add billions to Vertex's revenue tomorrow. But investing is often about protecting what already works. Vertex owns the cystic-fibrosis throne. One challenger just took a step backward. And the market is suddenly putting a bigger price on that moat. View Comments", "date_published": "2026-08-10T15:55:37+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "VRTX"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VRTX", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/fe76b9a5-9d69-445d-a49e-e107f61ffc89/"}]}}, {"id": "source:49be457c5beb197e8d56542c3cc33dd3537637da1ecb5fca8475f9aed49cd3d5", "url": "https://finance.yahoo.com/healthcare/articles/vertex-pharmaceuticals-vrtx-5-4-151413527.html", "external_url": "https://finance.yahoo.com/healthcare/articles/vertex-pharmaceuticals-vrtx-5-4-151413527.html", "title": "Vertex Pharmaceuticals (VRTX) Is Up 5.4% After Raising 2026 Revenue Guidance And Expanding Its Pipeline - Has The Bull Case Changed?", "content_text": "Vertex Pharmaceuticals recently reported second-quarter 2026 results, with revenue rising to US$3,333.9 million and net income reaching US$1,099.8 million, and raised its full-year 2026 revenue guidance to US$13.10\u2013US$13.20 billion. At the same time, a new collaboration with AbCellera on multispecific T\u2011cell engagers and a setback for a key cystic fibrosis competitor together highlight Vertex's efforts to broaden its pipeline while easing pressure on its core franchise. We'll now examine how Vertex's upgraded 2026 revenue guidance reshapes its existing investment narrative and the way investors may view future growth. Find 52 companies with promising cash flow potential yet trading below their fair value. Vertex Pharmaceuticals Investment Narrative Recap To own Vertex, you need to believe its cystic fibrosis engine can keep funding a broader portfolio in gene editing, pain and kidney disease, without margins slipping. The Q2 2026 beat and higher revenue guidance support that near term, while Sionna's cystic fibrosis setback temporarily eases competitive pressure. The key short term catalyst remains uptake of newer launches like CASGEVY and JOURNAVX, and the biggest risk is still how concentrated profits are in cystic fibrosis. The new AbCellera collaboration on multispecific T cell engagers fits directly into that diversification story, adding another potential pillar outside cystic fibrosis. It sits alongside ongoing CASGEVY label expansions and pain programs as part of the same catalyst: turning today's cash flows into a more balanced pipeline. How quickly these newer areas move from investment to meaningful revenue will shape how investors judge the upgraded US$13.10\u2013US$13.20 billion guidance in the context of future expectations. But while recent news may ease near term cystic fibrosis competition, investors should still be aware of how concentrated Vertex's profits remain... Read the full narrative on Vertex Pharmaceuticals (it's free!) Vertex Pharmaceuticals' narrative projects $17.2 billion revenue and $6.5 billion earnings by 2029. This requires 10.9% yearly revenue growth and about a $2.1 billion earnings increase from $4.4 billion today. Uncover how Vertex Pharmaceuticals' forecasts yield a $558.68 fair value, a 13% upside to its current price. Exploring Other PerspectivesVRTX 1-Year Stock Price Chart Some of the lowest ranked analysts were already assuming only about 6.8 percent annual revenue growth to roughly US$14.9 billion by 2029, so if you worry about pricing pressure and access constraints on high cost gene therapies, this new information could shift that more cautious story even further. Story Continues Explore 5 other fair value estimates on Vertex Pharmaceuticals - why the stock might be worth as much as 14% more than the current price! Reach Your Own Conclusion Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts. A great starting point for your Vertex Pharmaceuticals research is our analysis highlighting 3 key rewards that could impact your investment decision. Our free Vertex Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Vertex Pharmaceuticals' overall financial health at a glance. Curious About Other Options? Early movers are already taking notice. See the stocks they're targeting before they've flown the coop: This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality. Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution. We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology ", "date_published": "2026-08-10T15:14:13+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "VRTX"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VRTX", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/fe76b9a5-9d69-445d-a49e-e107f61ffc89/"}]}}, {"id": "source:d4a997611e99bc446034b28dc1f70a02e93aa3566bb24736a84a8d5453cff49e", "url": "https://finance.yahoo.com/m/228d5141-325a-32e3-b4da-3b347a2a5268/this-biotech%E2%80%99s-drug-could.html", "external_url": "https://finance.yahoo.com/m/228d5141-325a-32e3-b4da-3b347a2a5268/this-biotech%E2%80%99s-drug-could.html", "title": "This Biotech\u2019s Drug Could Treat Hot Flashes. The Stock Is Up 36% on Good News.", "content_text": "New data show a single dose of AbCellera\u2019s menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes. Continue Reading", "date_published": "2026-08-10T14:12:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "VRTX"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "VRTX", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/fe76b9a5-9d69-445d-a49e-e107f61ffc89/"}]}}, {"id": "source:465ba5a146eca7a17a9dddf98eb6236a85e588fd980e3cb89e4d06168ca9fb03", "url": "https://finance.yahoo.com/m/5448cf60-d94a-347d-90d3-c5b2cd4f502f/why-vertex-pharma-popped%2C-as.html", "external_url": "https://finance.yahoo.com/m/5448cf60-d94a-347d-90d3-c5b2cd4f502f/why-vertex-pharma-popped%2C-as.html", "title": "Why Vertex Pharma Popped, As A Key Rival Plummeted 90%", "content_text": "Vertex stock surged Monday after its competitor, Sionna Therapeutics, missed the mark for its highly anticipated cystic fibrosis treatment. Continue Reading", "date_published": "2026-08-10T13:22:53+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "VRTX"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VRTX", "name": "Vertex Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/fe76b9a5-9d69-445d-a49e-e107f61ffc89/"}]}}, {"id": "source:74366017fd2c0623307ac79147d5e34c80cb65bb87cd977037a35a42aa00bf8f", "url": "https://finance.yahoo.com/healthcare/articles/biomarin-participate-canaccord-genuity-46th-130500741.html", "external_url": "https://finance.yahoo.com/healthcare/articles/biomarin-participate-canaccord-genuity-46th-130500741.html", "title": "BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston", "content_text": "SAN RAFAEL, Calif., Aug. 10, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston.BioMarin Pharmaceutical logo An audio webcast of the presentation will be available live. The webcast can be accessed at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference. About BioMarin BioMarin is a leading, global rare disease biotechnolo", "date_published": "2026-08-10T13:05:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "BMRN"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BMRN", "name": "BioMarin Pharmaceutical Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/d0f5aa32-f8a9-4e82-af3c-242000942513/"}]}}, {"id": "source:d68b0a1d48719cb431f473b25ba4d707fa326d03aa64ef0c19ecde50c7fe852e", "url": "https://www.globenewswire.com/news-release/2026/08/09/3341497/9788/en/bronstein-gewirtz-grossman-llc-urges-regeneron-pharmaceuticals-inc-investors-to-act-class-action-filed-alleging-investor-harm.html", "external_url": "https://www.globenewswire.com/news-release/2026/08/09/3341497/9788/en/bronstein-gewirtz-grossman-llc-urges-regeneron-pharmaceuticals-inc-investors-to-act-class-action-filed-alleging-investor-harm.html", "title": "Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm", "content_text": "NEW YORK, Aug. 09, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Regeneron securities between August 1, 2025 and May 15, 2026, both dates inclusive (the \u201cClass Period\u201d). Such investors are encouraged to join this", "date_published": "2026-08-09T16:00:00+00:00", "authors": [{"name": "globenewswire.com"}], "tags": ["Regulatory and legal", "REGN"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "REGN", "name": "Regeneron Pharmaceuticals, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/fef373b5-80a0-4165-b299-994d5adb942b/"}]}}, {"id": "source:b34e1af58234f6b7dfa4cba07d4f7c14f25e85cad001b777845b73e7830cf0f0", "url": "https://seekingalpha.com/news/4629639-earnings-week-ahead-smci-csco-jd-plug-and-more?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4629639-earnings-week-ahead-smci-csco-jd-plug-and-more?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Earnings Week Ahead: SMCI, CSCO, JD, PLUG, and more", "content_text": "[Business Person Reviewing Quarterly Report During Meeting in Office Setting] The second full week of August features a diverse earnings slate spanning AI infrastructure, semiconductors, space technology, healthcare, financials, and consumer names, with Super Micro Computer (SMCI [https://seekingalpha.com/symbol/SMCI]), Nebius (NBIS [https://seekingalpha.com/symbol/NBIS]), Cisco Systems (CSCO [https://seekingalpha.com/symbol/CSCO]), CoreWeave (CRWV [https://seekingalpha.com/symbol/CRWV]), Applied Materials (AMAT [https://seekingalpha.com/symbol/AMAT]), and Lumentum (LITE [https://seekingalpha.", "date_published": "2026-08-09T12:07:00+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Earnings", "INO"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "INO", "name": "Inovio Pharmaceuticals, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/f766a58a-bff4-4514-82e8-d167c9f3b129/"}]}}, {"id": "source:2668ba56fc8490dfdf15ee7d2ca8fb74a8b9a2a4ea525fbefdc9b370d1a7b91c", "url": "https://finance.yahoo.com/markets/stocks/articles/regeneron-pharmaceuticals-regn-keeps-buybacks-231155132.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/regeneron-pharmaceuticals-regn-keeps-buybacks-231155132.html", "title": "Regeneron Pharmaceuticals (REGN) Keeps Buybacks And Dividend In Focus As Fair Value Stays In Sight", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Dividend, earnings and buybacks in focus Regeneron Pharmaceuticals (REGN) has given investors several fresh data points to consider after confirming a quarterly dividend, releasing second quarter and half year 2026 results, and updating on recent share repurchases. See our latest analysis for Regeneron Pharmaceuticals. Alongside the latest dividend and earnings update, Regeneron Pharmaceuticals' recent share price return of 18.33% over 30 days and 9.72% over 90 days suggests ", "date_published": "2026-08-08T23:11:55+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "REGN"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "REGN", "name": "Regeneron Pharmaceuticals, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/fef373b5-80a0-4165-b299-994d5adb942b/"}]}}, {"id": "source:34e4d37b4046b73310198faa81d3b6b3467b89da134ee73028afed440504502e", "url": "https://finance.yahoo.com/healthcare/articles/novavax-nvax-8-6-beating-101004083.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novavax-nvax-8-6-beating-101004083.html", "title": "Novavax (NVAX) Is Up 8.6% After Beating Q2 Estimates And Expanding Big-Pharma Partnerships - What's Changed", "content_text": "In early August 2026, Novavax reported Q2 2026 revenue of US$56.7 million, sharply lower than the prior year, and moved from net income to a net loss of US$53.39 million, translating into basic and diluted losses of US$0.32 per share from continuing operations. Alongside the weak year-on-year comparisons, Novavax beat analyst expectations for both revenue and earnings and highlighted progress on high-profile partnerships, including Sanofi and Pfizer, while also filing an US$82.47 million employee stock offering shelf registration. Now we'll examine how this mix of better-than-expected Q2 resul", "date_published": "2026-08-08T10:10:04+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "NVAX"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NVAX", "name": "Novavax, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/5636c4cf-7d84-42fb-bf59-c27bb981cb76/"}]}}, {"id": "source:a5cf899d529f747dc0db821317dc0878a2cd7ea99c9d5366e020468a75a5d349", "url": "https://finance.yahoo.com/healthcare/articles/ginkgo-bioworks-q2-earnings-call-040357271.html", "external_url": "https://finance.yahoo.com/healthcare/articles/ginkgo-bioworks-q2-earnings-call-040357271.html", "title": "Ginkgo Bioworks Q2 Earnings Call Highlights", "content_text": "Key Points Interested in Ginkgo Bioworks Holdings, Inc.? Here are five stocks we like better. Revenue fell sharply: Second-quarter 2026 revenue declined 48% year over year to $20 million, while net loss widened to $57 million and cash burn increased to $45 million. Ginkgo reaffirmed full-year cash-burn guidance of $125 million to $150 million. Autonomous labs remain the strategic focus: Ginkgo expanded its Boston Nebula facility to 105 racks and is pursuing projects with Pacific Northwest National Laboratory, MIT, Caltech, the University of Maryland and Northwestern University. New service off", "date_published": "2026-08-08T04:03:57+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Balance sheet", "DNA"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "DNA", "name": "Ginkgo Bioworks Holdings, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/bd0e4ac0-5171-421a-b6e7-d59461e303fe/"}]}}, {"id": "source:8c2967a817d4b5440004ff317104d2ca6f0b04853c79555e2b24b110d05f58c0", "url": "https://www.nasdaq.com/articles/moderna-mrna-q2-2026-earnings-call-transcript", "external_url": "https://www.nasdaq.com/articles/moderna-mrna-q2-2026-earnings-call-transcript", "title": "Moderna (MRNA) Q2 2026 Earnings Call Transcript", "content_text": "Image source: The Motley Fool. DATE Friday, July 31, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Chief Executive Officer - Stphane BancelPresident - Stephen HogeChief Financial Officer - James MockChief Development Officer - David Berman TAKEAWAYS Total Revenue -- $145 million, representing 2% growth driven by international strategic partnerships and stand-ready manufacturing revenue.Net Loss -- $782 million, an improvement of 5% compared to the prior year.Loss Per Share -- $1.97, improving from a loss of $2.13 in the second quarter of 2025.Cash and Investments -- $6.9 billion, a decrease from $7.5", "date_published": "2026-08-08T02:32:56+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "MRNA"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MRNA", "name": "Moderna, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/44b7313f-bff2-44ce-bdd7-cb74735027b8/"}]}}, {"id": "source:14892a30ae99fde61b079d7117aff51c4a2791d3130279e3b2323b5c2523db00", "url": "https://finance.yahoo.com/healthcare/articles/biontech-bntx-brings-ceo-europe-231157680.html", "external_url": "https://finance.yahoo.com/healthcare/articles/biontech-bntx-brings-ceo-europe-231157680.html", "title": "BioNTech (BNTX) Brings In New CEO As Europe Clears Updated COVID 19 Shot", "content_text": "Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. BioNTech (NasdaqGS:BNTX) named Dr. Guido Oelkers as incoming CEO, marking a major leadership transition at the company. The European Commission approved BioNTech's updated COVID-19 vaccine formula adapted for the XFG variant. The dual announcement links a change at the top with continued product development in COVID-19 vaccines. For readers looking to explore more stocks connected to the infrastructure behind this kind of va", "date_published": "2026-08-07T23:11:57+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BNTXN"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BNTXN", "name": "BioNTech SE", "sentiment_url": "https://sharemaestro.com/sentiment/30ac1e74-f59c-4c39-bcd8-ec38a42101e3/"}]}}, {"id": "source:f7f83e02985b763ca30cf30b38dc1be358a1283ea11c459cb80c2ef475dc9b44", "url": "https://finance.yahoo.com/markets/stocks/articles/incyte-reports-inducement-grants-under-203000999.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/incyte-reports-inducement-grants-under-203000999.html", "title": "Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "content_text": "WILMINGTON, Del., August 07, 2026--(BUSINESS WIRE)--Incyte Corporation (Nasdaq: INCY) announced today that it granted restricted stock unit awards (RSUs) representing an aggregate of 21,556 shares of the Company's common stock and stock option awards to purchase an aggregate of 18,172 shares of the Company's common stock to 24 new employees. The awards were made under the Company's 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of August 3, 2026, and were approved by the compensation committee of the Company's board of directors as an inducement material ", "date_published": "2026-08-07T20:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "INCY"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "INCY", "name": "Incyte Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/bfa37ebe-8823-4455-8296-972f2df07f8c/"}]}}, {"id": "source:6f2b5bde9fa5b37cff4f80b57bea9a0c6c1e3c2366f52c16e4ef704ed22b2664", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE1VQzZ0cXAycm5iUUo4eG1NbXo2QV9fbVBrOGp3Q3d1bC05dEs4WVpmdUx2YmlEekFyLUUtU2pEVEI3cTZVZXdZZjdGUlJ4UFVEQzB5M0RmdGRINWxlSGtQMTVEcjE?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE1VQzZ0cXAycm5iUUo4eG1NbXo2QV9fbVBrOGp3Q3d1bC05dEs4WVpmdUx2YmlEekFyLUUtU2pEVEI3cTZVZXdZZjdGUlJ4UFVEQzB5M0RmdGRINWxlSGtQMTVEcjE?oc=5", "title": "Noticias de acciones de Beam Therapeutics Inc (BEAM)", "content_text": "Noticias de acciones de Beam Therapeutics Inc (BEAM)", "date_published": "2026-08-07T19:37:09+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Market update", "BEAM"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BEAM", "name": "Beam Therapeutics Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/68e7fda6-e671-4517-a327-a9a7620e4811/"}]}}, {"id": "source:4c1e1ea2f70e021f4013626e3a2b2ae8492a6b7e62a9d41b666a67e482dca872", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE9RTVVIR2FZeElWc0FZVFdPT2l0MXE5OXI2dmQtdXVYOVhmN05rVXN0QXhNX1RlZDFtVmtxajNSRzFGbG5oMGQ0clprZWtjOWFuaDUzdkpHbUVWOUZxTDZVdDllc2E?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE9RTVVIR2FZeElWc0FZVFdPT2l0MXE5OXI2dmQtdXVYOVhmN05rVXN0QXhNX1RlZDFtVmtxajNSRzFGbG5oMGQ0clprZWtjOWFuaDUzdkpHbUVWOUZxTDZVdDllc2E?oc=5", "title": "Noticias de acciones de Sarepta Therapeutics Inc (SRPT)", "content_text": "Noticias de acciones de Sarepta Therapeutics Inc (SRPT)", "date_published": "2026-08-07T19:33:02+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Market update", "SRPT"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SRPT", "name": "SAREPTA THERAPEUTICS INC", "sentiment_url": "https://sharemaestro.com/sentiment/604cccad-4f2b-4f19-abc6-f185aac76766/"}]}}, {"id": "source:46787fb43fe73f7e7390fa5f3aae1fa0da22c04a8b1f8bf3b58143c57aa7f38c", "url": "https://finance.yahoo.com/healthcare/articles/nvax-q2-earnings-sales-beat-181800274.html", "external_url": "https://finance.yahoo.com/healthcare/articles/nvax-q2-earnings-sales-beat-181800274.html", "title": "NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook Raised", "content_text": "Novavax NVAX incurred a loss of 32 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 36 cents. In the year-ago quarter, the company had recorded earnings per share (EPS) of 62 cents, driven by milestone-related payments. Quarterly revenues totaled $56.7 million, down 76% year over year. Yet, this metric beat the Zacks Consensus Estimate of $50 million. Shares of Novavax have increased 14% so far this year compared with the industry's 4% growth.Zacks Investment Research Image Source: Zacks Investment Research NVAX's Revenue Mix Shifts Toward ", "date_published": "2026-08-07T18:18:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "NVAX"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NVAX", "name": "Novavax, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/5636c4cf-7d84-42fb-bf59-c27bb981cb76/"}]}}, {"id": "source:4a5b8dad45ed273bbe9e6a6e4a9f47bcb7ee5235226556b73baf2e7dba215b6f", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQUC12Wm8wcmgzcGpkaTh1YXpqSlV2S0RnalFRMEF4UmZwc1ZtUGVKWWNQNmhlcEUyaXNkUXhsdmdfaGdubjJTN0Z0Tl9KV3B4ODZhNzc0emtzVE5jeVVpYnlEUFNHWE5mVklZbFRodm9JYmtFZnJRaDFoMmxVMHBaQ245Wi1BZy1Ya3FOaFBzTG9TWDVvR3lHN1FYYkw4QjR5UGZ0MWdORUlReV9NN0h1NElQa2ZLUkVPVkxHNGZoRHRTZDlVZE5KWUtxaVVjaWRUUnpz?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQUC12Wm8wcmgzcGpkaTh1YXpqSlV2S0RnalFRMEF4UmZwc1ZtUGVKWWNQNmhlcEUyaXNkUXhsdmdfaGdubjJTN0Z0Tl9KV3B4ODZhNzc0emtzVE5jeVVpYnlEUFNHWE5mVklZbFRodm9JYmtFZnJRaDFoMmxVMHBaQ245Wi1BZy1Ya3FOaFBzTG9TWDVvR3lHN1FYYkw4QjR5UGZ0MWdORUlReV9NN0h1NElQa2ZLUkVPVkxHNGZoRHRTZDlVZE5KWUtxaVVjaWRUUnpz?oc=5", "title": "Informe de resultados de BioMarin Q2 2026: supera previsiones y mejora perspectivas", "content_text": "Informe de resultados de BioMarin Q2 2026: supera previsiones y mejora perspectivas", "date_published": "2026-08-06T22:14:00+00:00", "authors": [{"name": "Investing.com Espa\u00f1a"}], "tags": ["Market update", "BMRN"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BMRN", "name": "BioMarin Pharmaceutical Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/d0f5aa32-f8a9-4e82-af3c-242000942513/"}]}}, {"id": "source:39c06e83650dd2ce048476d35a4aa9caa0aae5a656be9ccbb5186ff66e1812b9", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxOLW1Zd3NHNXJ1eUtsUnpRYXcyZk11R3hpaWxJRkhCTmJDNFpVbFBzVGVSOE14Z1hsd3ZkNTF5RHM0WGQwRjcwV3E2cGNSZHlHQ3B4S3FFa2RQMG14Zy1Vc1pzc2xtWjhpcFhoRUQ3N1RLd1p3dGZqQ2RGdGprMGdHT1ZqcjNYTU05Z1hfV29NWkY3Vkk4SmhObUlBUThYbXZxdnJ2Mm11Qm9ZY1VzZi16Q1dPZE1VWGVlQUZQZUVWNThZeVhIVUVhYmZucmV5YVhyZGpRY0lPang?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxOLW1Zd3NHNXJ1eUtsUnpRYXcyZk11R3hpaWxJRkhCTmJDNFpVbFBzVGVSOE14Z1hsd3ZkNTF5RHM0WGQwRjcwV3E2cGNSZHlHQ3B4S3FFa2RQMG14Zy1Vc1pzc2xtWjhpcFhoRUQ3N1RLd1p3dGZqQ2RGdGprMGdHT1ZqcjNYTU05Z1hfV29NWkY3Vkk4SmhObUlBUThYbXZxdnJ2Mm11Qm9ZY1VzZi16Q1dPZE1VWGVlQUZQZUVWNThZeVhIVUVhYmZucmV5YVhyZGpRY0lPang?oc=5", "title": "Informe de resultados de Ardelyx: recorta previsiones y sus acciones caen en el Q2 2026", "content_text": "Informe de resultados de Ardelyx: recorta previsiones y sus acciones caen en el Q2 2026", "date_published": "2026-08-06T21:18:00+00:00", "authors": [{"name": "Investing.com Espa\u00f1a"}], "tags": ["Market update", "ARDX"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ARDX", "name": "Ardelyx, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/6dd0c444-ee0b-49e5-b374-0bd1374b8a27/"}]}}, {"id": "source:d11be4dbe1d262ad143a9f9df2d5a9b23fea34e5075f44f65cac677e4fed83d0", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxOcjBNT2w1ZEt5ajdyMUptUEhROTdZeURUVDlXUEphS2F5RlpDWmdnZmZqOXFZMFQwVElVU3ViQjdwS0FiX1A0eTcwQ0Z3VUxjWkh1cElOVXFJR1dENXJra1NOSXp1a2VSWlNwcVNscnpYVFBKQ09NNVJHeXlWTll4Slg3cGtsUmFrbFBrNENubHVGcl9HUzhqQ2xucDlmYlJjQ25ZWlZYNmxlcU5mMG45dlJGaWY4cUdlZVAzOWZkdGFYMmpxWGV4OTE2b3kwaDVrdEI0bDgtcW0wbTFNeWFnaUhac3p1M21rODNR?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxOcjBNT2w1ZEt5ajdyMUptUEhROTdZeURUVDlXUEphS2F5RlpDWmdnZmZqOXFZMFQwVElVU3ViQjdwS0FiX1A0eTcwQ0Z3VUxjWkh1cElOVXFJR1dENXJra1NOSXp1a2VSWlNwcVNscnpYVFBKQ09NNVJHeXlWTll4Slg3cGtsUmFrbFBrNENubHVGcl9HUzhqQ2xucDlmYlJjQ25ZWlZYNmxlcU5mMG45dlJGaWY4cUdlZVAzOWZkdGFYMmpxWGV4OTE2b3kwaDVrdEI0bDgtcW0wbTFNeWFnaUhac3p1M21rODNR?oc=5", "title": "BioMarin Pharmaceutical Inc. presenta sus previsiones de resultados para el tercer y cuarto trimestre de 2026", "content_text": "BioMarin Pharmaceutical Inc. presenta sus previsiones de resultados para el tercer y cuarto trimestre de 2026", "date_published": "2026-08-06T20:30:00+00:00", "authors": [{"name": "MarketScreener Espa\u00f1a"}], "tags": ["Market update", "BMRN"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BMRN", "name": "BioMarin Pharmaceutical Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/d0f5aa32-f8a9-4e82-af3c-242000942513/"}]}}, {"id": "source:43c90a13b89fc87083815b436a1b985748e11a33bbbb391b01e7bf67abea67c1", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQaklONlBUTVM1czloaGNmcTB4bWZUOWVTVE9LRHZ1dHJhR0xTazdsOW9wUl9ncFo3d25ZZ3JXeWJrMERUT0dtaEUtTlpTaUxGOGxaUUE1MEIwa3FZc0h5bDF4cmJvUjNqa2xxMnhGVmxlTFI0Z19kU0JKUy14ZzRRaUlkU2M0TlhBREpqY1JJUDN1UHJyaWN4aFJYS09QR3BnWl9xLUZzZEU2V1dsMnVVUFk4R01Ma2x0MGRoeDJDY3A0RXhQa1pqNVVfcVlCUllMeGc?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQaklONlBUTVM1czloaGNmcTB4bWZUOWVTVE9LRHZ1dHJhR0xTazdsOW9wUl9ncFo3d25ZZ3JXeWJrMERUT0dtaEUtTlpTaUxGOGxaUUE1MEIwa3FZc0h5bDF4cmJvUjNqa2xxMnhGVmxlTFI0Z19kU0JKUy14ZzRRaUlkU2M0TlhBREpqY1JJUDN1UHJyaWN4aFJYS09QR3BnWl9xLUZzZEU2V1dsMnVVUFk4R01Ma2x0MGRoeDJDY3A0RXhQa1pqNVVfcVlCUllMeGc?oc=5", "title": "Informe de resultados: Novavax supera estimaciones del Q2 2026 y eleva previsiones", "content_text": "Informe de resultados: Novavax supera estimaciones del Q2 2026 y eleva previsiones", "date_published": "2026-08-06T14:39:00+00:00", "authors": [{"name": "Investing.com Espa\u00f1a"}], "tags": ["Market update", "NVAX"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NVAX", "name": "Novavax, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/5636c4cf-7d84-42fb-bf59-c27bb981cb76/"}]}}, {"id": "source:4ad74685e683ca3e666d50d75cf22d42eeaf8dc51a28072d961c670fd0819fb0", "url": "https://news.google.com/rss/articles/CBMi_wFBVV95cUxNUFotcFRPMlY0UkFISGZZMVZTUEUzNm9KSDFJOTVvcHJDc3UwMEpqd0hjbTJ1dURwRFBSNmoyWlJhQ0NySjBmUHV0dGs1czFnUXUtZDMtMmc3c3EtS2NBTEVqUy1lZzJaZGVJSlFrZEFLeUp0U2hlRzAzR2FMdGdHQ1RTWlNNa3BnbXNKZUdEUXZoelI2N3VyQm5EdDhjYlIxYnFMYzlOS1NpYUpia3NPWnJYNTVOTXhTWFpiSE5VOFpnblZ2UnBXb2YtbVhxTXNlbHdMXzhVUmxfUU1Cb3hUb0hUMWE2eU02MFZhZEM4SEoyUGpKcDZZM1djY3ZmMzA?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi_wFBVV95cUxNUFotcFRPMlY0UkFISGZZMVZTUEUzNm9KSDFJOTVvcHJDc3UwMEpqd0hjbTJ1dURwRFBSNmoyWlJhQ0NySjBmUHV0dGs1czFnUXUtZDMtMmc3c3EtS2NBTEVqUy1lZzJaZGVJSlFrZEFLeUp0U2hlRzAzR2FMdGdHQ1RTWlNNa3BnbXNKZUdEUXZoelI2N3VyQm5EdDhjYlIxYnFMYzlOS1NpYUpia3NPWnJYNTVOTXhTWFpiSE5VOFpnblZ2UnBXb2YtbVhxTXNlbHdMXzhVUmxfUU1Cb3hUb0hUMWE2eU02MFZhZEM4SEoyUGpKcDZZM1djY3ZmMzA?oc=5", "title": "Informe de resultados de Ocugen: supera previsiones de ingresos en el segundo trimestre de 2026, pero ampl\u00eda p\u00e9rdidas", "content_text": "Informe de resultados de Ocugen: supera previsiones de ingresos en el segundo trimestre de 2026, pero ampl\u00eda p\u00e9rdidas", "date_published": "2026-08-06T13:31:00+00:00", "authors": [{"name": "Investing.com Espa\u00f1a"}], "tags": ["Market update", "OCGN"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "OCGN", "name": "Ocugen, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/9feac636-96f2-4cb4-9ae2-979e66131a4b/"}]}}, {"id": "source:c17738691fac8fa9ded597012cd9e659a15bf4c9045224e830d6fd2e9cb413ad", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQc194MHVQYlo2Y0d4bFhRaTV5YnBuYkJwdVRKbzl5U3RGZU5zWkRNckxTSGNaQUZTcmpKVnNHdFZaZlh6VkxERURFV0JoM0ZLZGYxQkJWbnVFZk1BWHFDS0UwYTJVbDJ3a2FaTE5sTThRQWpEV29PWFNqSW1lZjAzX0xLN25PZl9XbTcwQlRtZktLd0RQVnhCS0ZHeGxJaEhfc3BtZnFORmhlbThHeFhYcXRPZlQ0cGdiS21qQXJzYUFLNjcxY2lmNkJBOEY?oc=5", "external_url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQc194MHVQYlo2Y0d4bFhRaTV5YnBuYkJwdVRKbzl5U3RGZU5zWkRNckxTSGNaQUZTcmpKVnNHdFZaZlh6VkxERURFV0JoM0ZLZGYxQkJWbnVFZk1BWHFDS0UwYTJVbDJ3a2FaTE5sTThRQWpEV29PWFNqSW1lZjAzX0xLN25PZl9XbTcwQlRtZktLd0RQVnhCS0ZHeGxJaEhfc3BtZnFORmhlbThHeFhYcXRPZlQ0cGdiS21qQXJzYUFLNjcxY2lmNkJBOEY?oc=5", "title": "Informe de resultados de Ginkgo Bioworks: los ingresos del Q2 2026 decepcionan", "content_text": "Informe de resultados de Ginkgo Bioworks: los ingresos del Q2 2026 decepcionan", "date_published": "2026-08-05T23:14:00+00:00", "authors": [{"name": "Investing.com Espa\u00f1a"}], "tags": ["Market update", "DNA"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "DNA", "name": "Ginkgo Bioworks Holdings, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/bd0e4ac0-5171-421a-b6e7-d59461e303fe/"}]}}, {"id": "source:9851b8f3846e9a0ab1c54ec23bf024c05b49d28356ca747244344ac4298c86b6", "url": "https://news.google.com/rss/articles/CBMingJBVV95cUxOMi1idmJNNlUwWGFIcnNZa3RvWm1oV25xTGhLandHS1Q4TzhvaVNrQk1DV196OTA0MTdCYnc2MXZTUE1KUDB2MlNwVEFaOFh5TzFMYlNGbzA5YlZ2dlhpaE53WG1MQmRaSjhhLW5ILXZTaERsMU0wQ3AyTWd4M1V6NWp0OURKT0dnOXJ4cUxHd2FITzJ0a0N6ck9ESGRDQVVQSk1hR25aUFA3bUR5YW9LUVhSd05QM0N1X1g4VVZXYjNnV1FyY3Bnb2JESDdkS09hSFVsREhoZTF0bFhFVkRSdm5VbXR2SFNtNmpSWWRBOUk2VWVFUGZfd0pPMzFRSU0tbHVqZVNJQVhXa2ZyRG5waWpLMXJ0ZFIzSUJmejFR?oc=5", "external_url": "https://news.google.com/rss/articles/CBMingJBVV95cUxOMi1idmJNNlUwWGFIcnNZa3RvWm1oV25xTGhLandHS1Q4TzhvaVNrQk1DV196OTA0MTdCYnc2MXZTUE1KUDB2MlNwVEFaOFh5TzFMYlNGbzA5YlZ2dlhpaE53WG1MQmRaSjhhLW5ILXZTaERsMU0wQ3AyTWd4M1V6NWp0OURKT0dnOXJ4cUxHd2FITzJ0a0N6ck9ESGRDQVVQSk1hR25aUFA3bUR5YW9LUVhSd05QM0N1X1g4VVZXYjNnV1FyY3Bnb2JESDdkS09hSFVsREhoZTF0bFhFVkRSdm5VbXR2SFNtNmpSWWRBOUk2VWVFUGZfd0pPMzFRSU0tbHVqZVNJQVhXa2ZyRG5waWpLMXJ0ZFIzSUJmejFR?oc=5", "title": "Informe de resultados de Sarepta: supera las estimaciones del segundo trimestre de 2026 y sus acciones suben en el mercado fuera de horario", "content_text": "Informe de resultados de Sarepta: supera las estimaciones del segundo trimestre de 2026 y sus acciones suben en el mercado fuera de horario", "date_published": "2026-08-05T22:25:00+00:00", "authors": [{"name": "Investing.com Espa\u00f1a"}], "tags": ["Market update", "SRPT"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SRPT", "name": "SAREPTA THERAPEUTICS INC", "sentiment_url": "https://sharemaestro.com/sentiment/604cccad-4f2b-4f19-abc6-f185aac76766/"}]}}, {"id": "source:3e622a573cbdce018bf26ddaccd036abf60497e42a74ca9bb10768eb1efbb835", "url": "https://news.google.com/rss/articles/CBMilwJBVV95cUxOTlZtV1dvWXkxaER0NlZncU94UzlDRUktZXY4VHNidzI2c0VTdF8yd2NRU2dTR2lZS3dSazlRVi1CUEVhVExrVkFnVVFUSUF4SGd2THhqYnlaWWlHVzY3MmRGVTF3b25UM0ZnYnVyUU1sdFk3bHNKN1RtLVFFNmU5VGg2UU85WjdLSEJqajYzLWpvSEJUUHNPUmxZRC1iLXZ2dVM2cEN4MnBvcEhuODBJdUNXdk5jSm5fYVpJNnVRTFY5Rl9jenBBWEYtRkhSSm8yZzlNN1oySktnVGdodUMxNWp3M001OVZkR0RnOW5Vd3pnWDI1ZWNUZ3R0YWRCcjdGeDRJdTZXTmdoOXRUUUlMOWpRdnIzZFU?oc=5", "external_url": "https://news.google.com/rss/articles/CBMilwJBVV95cUxOTlZtV1dvWXkxaER0NlZncU94UzlDRUktZXY4VHNidzI2c0VTdF8yd2NRU2dTR2lZS3dSazlRVi1CUEVhVExrVkFnVVFUSUF4SGd2THhqYnlaWWlHVzY3MmRGVTF3b25UM0ZnYnVyUU1sdFk3bHNKN1RtLVFFNmU5VGg2UU85WjdLSEJqajYzLWpvSEJUUHNPUmxZRC1iLXZ2dVM2cEN4MnBvcEhuODBJdUNXdk5jSm5fYVpJNnVRTFY5Rl9jenBBWEYtRkhSSm8yZzlNN1oySktnVGdodUMxNWp3M001OVZkR0RnOW5Vd3pnWDI1ZWNUZ3R0YWRCcjdGeDRJdTZXTmdoOXRUUUlMOWpRdnIzZFU?oc=5", "title": "Informe de resultados: Recursion no alcanza previsiones de ingresos en el Q2 2026 y sus acciones caen antes de la apertura del mercado", "content_text": "Informe de resultados: Recursion no alcanza previsiones de ingresos en el Q2 2026 y sus acciones caen antes de la apertura del mercado", "date_published": "2026-08-05T13:12:00+00:00", "authors": [{"name": "Investing.com Espa\u00f1a"}], "tags": ["Market update", "RXRX"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "RXRX", "name": "RECURSION PHARMACEUTICALS INC", "sentiment_url": "https://sharemaestro.com/sentiment/7bb72e3e-f732-4308-b18d-13845b1a4811/"}]}}]}